First AD

Second AD

Detecting HER2 expression by IHC in lung cancer, the role of ADCs in targeting 

mutations, and the FDA breakthrough designation for trastuzumab deruxtecan are examined.

Data from the following clinical trials are discussed:

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with 

-mutated metastatic non–small cell lung cancer: Interim results of DESTINY-Lung01. (Smit EF et al. 2020 ASCO annual meeting. Abstract 9504.)

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

HER2 Targeted Therapy for Treatment of NSCLC

Data from the following clinical trials are discussed:

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non–small cell lung cancer: Interim results of DESTINY-Lung01. (Smit EF et al. 2020 ASCO annual meeting. Abstract 9504.)